Plau Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Plau Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [1]
The PLAU protein (Plasminogen Activator, Urokinase), also known as urokinase-type plasminogen activator (uPA), is a serine protease that converts plasminogen to plasmin. It has roles in fibrinolysis, extracellular proteolysis, and cell migration. [2]
| Attribute | Value | [3]
|-----------|-------| [4]
| Protein Name | Urokinase-type Plasminogen Activator |
| Gene Symbol | PLAU |
| UniProt ID | P00750 |
| Molecular Weight | 52 kDa (pro-uPA), 33 kDa (active) |
| Subcellular Localization | Extracellular, cell surface |
| Protein Family | Serine protease family |
PLAU has a typical serine protease structure:
Urokinase is a key fibrinolytic enzyme:
PLAU is expressed in:
| Drug | Mechanism | Status |
|---|---|---|
| Urokinase | Plasminogen activation | Approved (某些国家) |
| tPA | Plasminogen activation | Approved (stroke) |
| uPA derivatives | Modified activity | Research |
The urokinase-type plasminogen activator (uPA) plays multiple roles in neurodegeneration:
PLAU catalyzes the conversion of plasminogen to plasmin:
uPA-mediated proteolysis affects:
uPA binds to the uPA receptor (uPAR):
PLAU is expressed in:
PLAU and its inhibitor PAI-1 have been studied as biomarkers:
| Condition | PLAU Level | PAI-1 Level | Utility |
|---|---|---|---|
| Stroke | Elevated | Elevated | Prognosis |
| AD | Elevated | Elevated | Disease marker |
| PD | Variable | Elevated | Progression |
| TBI | Elevated | Elevated | Outcome |
Plau Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Plau Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Critchley RJ, et al. (1999). PLAU in neurodegeneration. Critchley RJ, et al. 1999. ↩︎
Tucker HM, et al. (2000). Urokinase-type plasminogen activator in AD. Tucker HM, et al. 2000. ↩︎
Emilen J, et al. (2010). PLAU and neuroinflammation. Emilen J, et al. 2010. ↩︎
Cao C, et al. (2018). PLAU as therapeutic target. Cao C, et al. 2018. ↩︎